Analgesics
Antiandrogens
Antihistamines
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
TMPRSS2 inh.
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchSelect treatment..Select..
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta
Thermotherapy Meta
Melatonin Meta
Metformin Meta

 

COVIDOSE-2: A Multi-center, Randomized, Controlled Phase 2 Trial Comparing Early Administration of Low-dose Tocilizumab to Standard of Care in Hospitalized Patients With COVID-19 Pneumonitis Not Requiring Invasive Ventilation

Reid et al., NCT04479358, COVIDOSE-2, NCT04479358, Feb 2025
https://c19early.org/reid.html
Mortality, all -56% Improvement Relative Risk Mortality, 120mg 66% Mortality, 40mg -212% Recovery time, all pati.. -2% Recovery time, 120mg 20% Recovery time, 40mg -40% Tocilizumab  COVIDOSE-2  LATE TREATMENT  RCT Is late treatment with tocilizumab beneficial for COVID-19? RCT 85 patients in the USA Trial underpowered for serious outcomes c19early.org Reid et al., NCT04479358, February 2025 Favorstocilizumab Favorscontrol 0 0.5 1 1.5 2+
RCT 85 patients in the USA showing no significant differences with tocilizumab treatment.
Standard of Care (SOC) for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
risk of death, 56.0% higher, RR 1.56, p = 1.00, treatment 3 of 50 (6.0%), control 1 of 26 (3.8%), all patients.
risk of death, 66.2% lower, RR 0.34, p = 1.00, treatment 0 of 25 (0.0%), control 1 of 26 (3.8%), NNT 26, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm), 120mg.
risk of death, 212.0% higher, RR 3.12, p = 0.35, treatment 3 of 25 (12.0%), control 1 of 26 (3.8%), 40mg.
recovery time, 2.5% higher, relative time 1.02, p = 0.94, treatment 25, control 26, all patients.
recovery time, 20.0% lower, relative time 0.80, p = 0.09, treatment mean 4.0 (±1.28) n=25, control mean 5.0 (±2.6) n=26, 120mg.
recovery time, 40.0% higher, relative time 1.40, p = 0.15, treatment mean 7.0 (±6.38) n=25, control mean 5.0 (±2.6) n=26, 40mg.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Reid et al., 10 Feb 2025, Randomized Controlled Trial, USA, preprint, 1 author, trial NCT04479358 (history) (COVIDOSE-2). Contact: pankti.reid@bsd.uchicago.edu.
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. IMA and WCH provide treatment protocols.
  or use drag and drop   
Submit